Skip to main content
Book cover

Psychopathology in Women pp 739–764Cite as

Gender Differences in Bipolar Disorder

Abstract

The main objective of this chapter is to summarize the clinical differences found in the literature between men and women suffering from bipolar disorder. The secondary objective is to analyze the treatment and how there are gender differences in the adherence to medication. Briefly, we could say that in men the manic component predominates, both at onset and throughout their lifetime, and that they usually have comorbid drug abuse. On the other hand, women usually tend to have a predominance of depression; they have a depressive polarity both at onset and during their lifetime and experience more mixed mania episodes. Furthermore, in women onset often occurs at an older age, comorbidity of physical pathological conditions is common, and adherence to medication is greater than in men.

We cannot forget that women can experience two very important periods: pregnancy and postpartum. Both can be critical periods for the disorder, and a relapse or recurrence at either stage can have serious consequences not just for the woman but also for her baby. Because the effect of medication on the fetus still remains unclear, it makes it even more difficult to set the treatment during these periods.

Keywords

  • Bipolar disorder
  • Gender
  • Differences
  • Woman
  • Pregnancy

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-15179-9_31
  • Chapter length: 26 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-15179-9
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   169.99
Price excludes VAT (USA)
Hardcover Book
USD   249.99
Price excludes VAT (USA)
Learn about institutional subscriptions

References

  1. Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–51.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013.

    Google Scholar 

  3. Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J, et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord. 1998;50(1):41–4.

    CrossRef  CAS  PubMed  Google Scholar 

  4. López-Zurbano S, González-Pinto A, López P. Gender differences in bipolar disorder. In: Psychopathology in women. Cham: Springer; 2015. p. 641–59.

    Google Scholar 

  5. Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C. Gender and bipolar illness. J Clin Psychiatry. 2000;61(5):393–6.. quiz 397

    CrossRef  CAS  PubMed  Google Scholar 

  6. Popovic D, Torrent C, Goikolea JM, Cruz N, Sánchez-Moreno J, González-Pinto A, et al. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand. 2014;129(5):366–74.

    CrossRef  CAS  PubMed  Google Scholar 

  7. Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry. 2010;71(6):e14.

    CrossRef  PubMed  Google Scholar 

  8. Karanti A, Bobeck C, Osterman M, Kardell M, Tidemalm D, Runeson B, et al. Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients. J Affect Disord. 2015;174:303–9.

    CrossRef  PubMed  Google Scholar 

  9. Nivoli AMA, Pacchiarotti I, Rosa AR, Popovic D, Murru A, Valenti M, et al. Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. J Affect Disord. 2011;133(3):443–9.

    CrossRef  PubMed  Google Scholar 

  10. Azorin J-M, Belzeaux R, Kaladjian A, Adida M, Hantouche E, Lancrenon S, et al. Risks associated with gender differences in bipolar I disorder. J Affect Disord. 2013;151(3):1033–40.

    CrossRef  PubMed  Google Scholar 

  11. Rasgon N, Bauer M, Glenn T, Elman S, Whybrow PC. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003;5(1):48–52.

    CrossRef  PubMed  Google Scholar 

  12. Kawa I, Carter JD, Joyce PR, Doughty CJ, Frampton CM, Wells JE, et al. Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord. 2005;7(2):119–25.

    CrossRef  PubMed  Google Scholar 

  13. Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, et al. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167(6):708–15.

    CrossRef  PubMed  Google Scholar 

  14. Saunders EFH, Fitzgerald KD, Zhang P, McInnis MG. Clinical features of bipolar disorder comorbid with anxiety disorders differ between men and women. Depress Anxiety. 2012;29(8):739–46.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  15. Bhattacharya A, Khess CRJ, Munda SK, Bakhla AK, Praharaj SK, Kumar M. Sex difference in symptomatology of manic episode. Compr Psychiatry. 2011;52(3):288–92.

    CrossRef  PubMed  Google Scholar 

  16. Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63(4):284–7.

    CrossRef  PubMed  Google Scholar 

  17. Drancourt N, Etain B, Lajnef M, Henry C, Raust A, Cochet B, et al. Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand. 2013;127(2):136–44.

    CrossRef  CAS  PubMed  Google Scholar 

  18. Benazzi F. Gender differences in bipolar II and unipolar depressed outpatients: a 557-case study. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 1999;11(2):55–9.

    CrossRef  CAS  Google Scholar 

  19. Hirschfeld RMA, Vornik LA. Recognition and diagnosis of bipolar disorder. J Clin Psychiatry. 2004;65(Suppl 15):5–9.

    PubMed  Google Scholar 

  20. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63(11):985–91.

    CrossRef  PubMed  Google Scholar 

  21. Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–74.

    CrossRef  PubMed  Google Scholar 

  22. González-Pinto A, Aldama A, González C, Mosquera F, Arrasate M, Vieta E. Predictors of suicide in first-episode affective and nonaffective psychotic inpatients: five-year follow-up of patients from a catchment area in Vitoria. Spain J Clin Psychiatry. 2007;68(2):242–7.

    CrossRef  PubMed  Google Scholar 

  23. Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Vieta E. Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatry. 2012;73(6):778–82.

    CrossRef  PubMed  Google Scholar 

  24. López P, Mosquera F, de León J, Gutiérrez M, Ezcurra J, Ramírez F, et al. Suicide attempts in bipolar patients. J Clin Psychiatry. 2001;62(12):963–6.

    CrossRef  PubMed  Google Scholar 

  25. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Introduction Acta Psychiatr Scand Suppl. 1966;194:9–14.

    CrossRef  CAS  PubMed  Google Scholar 

  26. Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Arch Gen Psychiatry. 1992;49(2):126–31.

    CrossRef  CAS  PubMed  Google Scholar 

  27. Rasgon N, Bauer M, Grof P, Gyulai L, Elman S, Glenn T, et al. Sex-specific self-reported mood changes by patients with bipolar disorder. J Psychiatr Res. 2005;39(1):77–83.

    CrossRef  PubMed  Google Scholar 

  28. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6(1):2–13.

    CrossRef  CAS  PubMed  Google Scholar 

  29. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152(8):1130–8.

    CrossRef  CAS  PubMed  Google Scholar 

  30. Lee S, Tsang A, Kessler RC, Jin R, Sampson N, Andrade L, et al. Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry J Ment Sci. 2010;196(3):217–25.

    CrossRef  Google Scholar 

  31. Bräunig P, Sarkar R, Effenberger S, Schoofs N, Krüger S. Gender differences in psychotic bipolar mania. Gend Med. 2009;6(2):356–61.

    CrossRef  PubMed  Google Scholar 

  32. Delvecchio G, Ciappolino V, Perlini C, Barillari M, Ruggeri M, Altamura AC, et al. Correction to: cingulate abnormalities in bipolar disorder relate to gender and outcome: a region-based morphometry study. Eur Arch Psychiatry Clin Neurosci. 2018; https://doi.org/10.1007/s00406-018-0913-3

  33. Gressier F, Calati R, Serretti A. 5-HTTLPR and gender differences in affective disorders: a systematic review. J Affect Disord. 2016;190:193–207.

    CrossRef  CAS  PubMed  Google Scholar 

  34. De Almeida IB, Nardi AE, De Ornelas Maia AC, Levitan M. Estrogen and transdiagnostics: a systematic review. J Depress Anxiety. 2016;5(228):2167–1044.

    Google Scholar 

  35. Meinhard N, Kessing LV, Vinberg M. The role of estrogen in bipolar disorder, a review. Nord J Psychiatry febrero de. 2014;68(2):81–7.

    CrossRef  Google Scholar 

  36. Kenna HA, Jiang B, Rasgon NL. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv Rev Psychiatry. 2009;17(2):138–46.

    CrossRef  PubMed  Google Scholar 

  37. Fellinger M, Waldhör T, Blüml V, Williams N, Vyssoki B. Influence of gender on inpatient treatment for bipolar disorder: an analysis of 60,607 hospitalisations. J Affect Disord. 2018;225:104–7.

    CrossRef  PubMed  Google Scholar 

  38. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci JPN. 2002;27(2):104–7.

    PubMed  Google Scholar 

  39. Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8(5 Pt 2):618–24.

    CrossRef  CAS  PubMed  Google Scholar 

  40. Colom F, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61(8):549–55.

    CrossRef  CAS  PubMed  Google Scholar 

  41. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153(8):993–1000.

    CrossRef  CAS  PubMed  Google Scholar 

  42. Vega P, Hernández M, Martinez-Cengotitabengoa M, Gonzalez I. Why do bipolar men not comply with treatment? Int Clin Psychopharmacol. 2011;26(39):63–9.

    Google Scholar 

  43. Lang K, Korn J, Muser E, Choi JC, Abouzaid S, Menzin J. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ. 2011;14(2):217–26.

    CrossRef  PubMed  Google Scholar 

  44. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105.

    CrossRef  PubMed  Google Scholar 

  45. Kriegshauser K, Sajatovic M, Jenkins JH, Cassidy KA, Muzina D, Fattal O, et al. Gender differences in subjective experience and treatment of bipolar disorder. J Nerv Ment Dis. 2010;198(5):370–2.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  46. Leskelä U, Melartin T, Rytsälä H, Jylhä P, Sokero P, Lestelä-Mielonen P, et al. Influence of personality on objective and subjective social support among patients with major depressive disorder: a prospective study. J Nerv Ment Dis. 2009;197(10):728–35.

    CrossRef  PubMed  Google Scholar 

  47. Franzoi SL, Koehler V. Age and gender differences in body attitudes: a comparison of young and elderly adults. Int J Aging Hum Dev. 1998;47(1):1–10.

    CrossRef  CAS  PubMed  Google Scholar 

  48. Trede K, Baldessarini RJ, Viguera AC, Bottero A. Treatise on insanity in pregnant, postpartum, and lactating women (1858) by Louis-Victor Marcé: a commentary. Harv Rev Psychiatry. 2009;17(2):157–65.

    CrossRef  PubMed  Google Scholar 

  49. Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168(11):1179–85.

    CrossRef  PubMed  Google Scholar 

  50. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24; quiz 1923

    CrossRef  PubMed  Google Scholar 

  51. Mateo MJZ, Albéniz JM, Yañez LP. uso de psicofarmacos durante el embarazo y la lactancia. 2nd ed. Osakidetza: Vitoria-Gasteiz (Álava); 2016.

    Google Scholar 

  52. Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum depression: Detection, diagnosis, and treatment. Am J Psychiatry. 2009;166(11):1217–21.

    CrossRef  PubMed  Google Scholar 

  53. Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet Lond Engl. 2014;384(9956):1789–99.

    CrossRef  Google Scholar 

  54. Heron J, Haque S, Oyebode F, Craddock N, Jones I. A longitudinal study of hypomania and depression symptoms in pregnancy and the postpartum period. Bipolar Disord. 2009;11(4):410–7.

    CrossRef  PubMed  Google Scholar 

  55. Sharma V, Khan M, Corpse C, Sharma P. Missed bipolarity and psychiatric comorbidity in women with postpartum depression. Bipolar Disord. 2008;10(6):742–7.

    CrossRef  PubMed  Google Scholar 

  56. Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ. 2018;361:k1596.

    CrossRef  PubMed  Google Scholar 

  57. National Institute for Health and Care Excellence. NICE. Bipolar disorder: assessment and management. 2014.

    Google Scholar 

  58. Jauhar S, McKenna PJ, Laws KR. NICE guidance on psychological treatments for bipolar disorder: searching for the evidence. Lancet Psychiatry. 2016;3(4):386–8.

    CrossRef  PubMed  Google Scholar 

  59. Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.

    CrossRef  PubMed  PubMed Central  CAS  Google Scholar 

  60. National Institute for Health and Care Excellence. NICE. Antenatal and postnatal mental health: clinical management and service guidance. In: NICE. 2014.

    Google Scholar 

  61. Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol. 2009;52(3):469–82.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  62. Álamo C, Alonso Z, Alvarez I. In: salazar M, Peral C, Pastor FJ, editors. Manejo de psicofármacos en situaciones vitales específicas. Manual de Psicofarmacología. Madrid: Editoral Médica Panamericana; 2011. p. 87–92.

    Google Scholar 

  63. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–92.

    CrossRef  PubMed  Google Scholar 

  64. ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001–20.

    Google Scholar 

  65. Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918.

    CrossRef  CAS  PubMed  Google Scholar 

  66. Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf. 2012;11(3):425–37.

    CrossRef  CAS  PubMed  Google Scholar 

  67. arcía-Esteve LL (último), Valdés Miyar. Manual de Psiquiatría perinatal. Guía para el manejo de los trastornos mentales durante el embarazo, posparto y lactancia. Madrid: Médica Panamerican; 2016.

    Google Scholar 

  68. Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224–35.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  69. Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry. 2011;24(1):34–40.

    CrossRef  PubMed  Google Scholar 

  70. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50.

    CrossRef  CAS  PubMed  Google Scholar 

  71. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet Lond Engl. 2012;379(9817):721–8.

    CrossRef  CAS  Google Scholar 

  72. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006;8(3):207–20.

    CrossRef  CAS  PubMed  Google Scholar 

  73. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8.

    CrossRef  CAS  PubMed  Google Scholar 

  74. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68(10):1275–81.

    CrossRef  PubMed  Google Scholar 

  75. Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurol. 2018;75(6):663–71.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  76. Kälviäinen R, Straus S, Dogne J-M, Bakchine S, Haas M. Reducing valproate use in women with epilepsy. Lancet Neurol. 2018;17(7):580–1.

    CrossRef  PubMed  Google Scholar 

  77. Wieck A, Jones S. Dangers of valproate in pregnancy. BMJ. 2018;361:k1609.

    CrossRef  PubMed  Google Scholar 

  78. FDA, US. FDA Drug Safety Communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. FDA website; 2018.

    Google Scholar 

  79. European Medicines Agency. PRAC recommends new measures to avoid valproate exposure in pregnancy [Internet]. 2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002903.jsp&mid=WC0b01ac058004d5c1.

  80. National Collaborating Centre for Mental Health. Antenatal and postnatal mental health: the NICE guideline on clinical management and service guidance. British Psychological Society; 2007.

    Google Scholar 

  81. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LTW, EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22.

    CrossRef  CAS  PubMed  Google Scholar 

  82. Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–46.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  83. Food and Drug Administration. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns [Internet]. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm243903.

  84. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36(3):518–44.

    CrossRef  PubMed  Google Scholar 

  85. Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. Arch Womens Ment Health. 2017;20(1):1–9.

    CrossRef  PubMed  Google Scholar 

  86. Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry. 2009;70(3):414–22.

    CrossRef  CAS  PubMed  Google Scholar 

  87. Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317(15):1553–62.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  88. Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf. 2005;28(7):565–81.

    CrossRef  CAS  PubMed  Google Scholar 

  89. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.

    CrossRef  CAS  PubMed  Google Scholar 

  90. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA. 2017;317(15):1544–52.

    CrossRef  CAS  PubMed  Google Scholar 

  91. Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: a systematic review of epidemiological and physiological evidence. Int J Risk Saf Med. 2016;28(3):125–41.

    CrossRef  CAS  PubMed  Google Scholar 

  92. Enato E, Moretti M, Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011;33(1):46–8.

    CrossRef  PubMed  Google Scholar 

  93. Rasmussen K. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (second edition). J ECT. 2002;18(1):58–9.

    CrossRef  PubMed  Google Scholar 

  94. Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011;117(4):961–77.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alava University Hospital, Vitoria, Spain

    Saioa López-Zurbano & Ana González-Pinto

  2. University of the Basque Country UPV/EHU, Leioa, Guipúzcoa, Spain

    Saioa López-Zurbano & Ana González-Pinto

  3. CIBERSAM, Barcelona, Spain

    Ana González-Pinto

Authors
  1. Saioa López-Zurbano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana González-Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cruces University Hospital, University of the Basque Country, Barakaldo, Vizcaya, Spain

    Dr. Margarita Sáenz-Herrero

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

López-Zurbano, S., González-Pinto, A. (2019). Gender Differences in Bipolar Disorder. In: Sáenz-Herrero, M. (eds) Psychopathology in Women. Springer, Cham. https://doi.org/10.1007/978-3-030-15179-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-15179-9_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-15178-2

  • Online ISBN: 978-3-030-15179-9

  • eBook Packages: MedicineMedicine (R0)